As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Tarsus Pharmaceuticals Inc. The largest reported stake is Deep Track Capital, LP's, at 8.46%. 11 filings are on record since July 28, 2025 (Schedule 13G/A, May 15, 2026).
Sell to companies like Tarsus Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Fmr LLC · Sole voting: 3,139,690 · Shared voting: 0 · Sole dispositive: 3,143,158 · Shared dispositive: 0 · SCHEDULE 13G, 2026-11-05
- · Reporting person: JANUS HENDERSON GROUP Ltd. · Sole voting: 0 · Shared voting: 2,808,796 · Sole dispositive: 0 · Shared dispositive: 2,808,796 · SCHEDULE 13G/A, 2026-08-13
- · Reporting person: Deep Track Capital, LP · Sole voting: 0 · Shared voting: 3,600,000 · Sole dispositive: 0 · Shared dispositive: 3,600,000 · SCHEDULE 13G/A, 2026-05-15
- · Holder: Janus Henderson Group Plc · Percent: 5.3% · SCHEDULE 13G
- · Reporting person: Prudential Financial Inc · Sole voting: 0 · Shared voting: 1,670,648 · Sole dispositive: 0 · Shared dispositive: 1,836,321 · SCHEDULE 13G/A, 2026-05-08
Tarsus Pharmaceuticals Inc has 11 Schedule 13D or 13G filings on record since 2025-07-28. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Deep Track Capital, LP | 8.46% | 3,600,000 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| RTW Investments, LP | 8.1% | 3,424,180 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| JANUS HENDERSON GROUP Ltd. | 6.5% | 2,808,796 | SCHEDULE 13G/A, 2026-08-13 | 2026-06-30 |
| Fmr LLC | 6.4% | 3,143,158 | SCHEDULE 13G, 2026-11-05 | 2026-09-30 |
| Prudential Financial Inc | 4.3% | 1,836,321 | SCHEDULE 13G/A, 2026-05-08 | 2026-03-31 |
| Jennison Associates LLC | 4% | 1,712,124 | SCHEDULE 13G/A, 2026-05-06 | 2026-03-31 |
| Tang Capital Management, LLC | 2.8% | 1,188,624 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Tarsus Pharmaceuticals Inc and the warning signs.
Free to see. No signup.
Keep reading
More on Tarsus Pharmaceuticals Inc and the records around it.
Tarsus Pharmaceuticals Inc elsewhere on the record
- Acquisition Sep 2026
- Who owns it
Companies that share a holder
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), PALVELLA THERAPEUTICS INC (Oct 2026), REZOLUTE INC (Oct 2026)
- PRUDENTIAL FINANCIAL INC also filed stake reports on 20 other companies: National Healthcare Properties, Inc. (Oct 2026), Neurogene Inc. (Oct 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
Watch Tarsus Pharmaceuticals Inc
Get an email when Tarsus Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Tarsus Pharmaceuticals Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Tarsus Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Tarsus Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 0 | 3,600,000 | 0 | 3,600,000 | SCHEDULE 13G/A, 2026-05-15 |
| Deep Track Biotechnology Master Fund, Ltd. | 0 | 3,600,000 | 0 | 3,600,000 | SCHEDULE 13G/A, 2026-05-15 |
| David Kroin | 0 | 3,600,000 | 0 | 3,600,000 | SCHEDULE 13G/A, 2026-05-15 |
| JANUS HENDERSON GROUP Ltd. | 0 | 2,808,796 | 0 | 2,808,796 | SCHEDULE 13G/A, 2026-08-13 |
| Fmr LLC | 3,139,690 | 0 | 3,143,158 | 0 | SCHEDULE 13G, 2026-11-05 |
| Abigail P. Johnson | 0 | 0 | 3,143,158 | 0 | SCHEDULE 13G, 2026-11-05 |
| Prudential Financial Inc | 0 | 1,670,648 | 0 | 1,836,321 | SCHEDULE 13G/A, 2026-05-08 |
The latest filing identifies Tarsus Pharmaceuticals Inc by CUSIP 87650L103 and gives its principal executive office as 15440 LAGUNA CANYON ROAD, IRVINE, CA 92618 (SCHEDULE 13G, 2026-11-05).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-28 | Deep Track Capital, LP | 5.6% | SCHEDULE 13G |
| 2025-08-14 | RTW Investments, LP | 8.1% | SCHEDULE 13G/A |
| 2025-11-14 | Deep Track Capital, LP | 7.11% | SCHEDULE 13G/A |
| 2026-02-17 | Tang Capital Management, LLC | 2.8% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-06 | Jennison Associates LLC | 4% | SCHEDULE 13G/A |
| 2026-05-08 | Prudential Financial Inc | 4.3% | SCHEDULE 13G/A |
| 2026-05-15 | Deep Track Capital, LP | 8.46% | SCHEDULE 13G/A |
| 2026-05-15 | Janus Henderson Group Plc | 5.3% | SCHEDULE 13G |
| 2026-08-13 | JANUS HENDERSON GROUP Ltd. | 6.5% | SCHEDULE 13G/A |
| 2026-11-05 | Fmr LLC | 6.4% | SCHEDULE 13G |
Questions about who owns Tarsus Pharmaceuticals Inc
Who owns Tarsus Pharmaceuticals Inc?
On this page, 4 holders' latest ownership filings report 5% or more of Tarsus Pharmaceuticals Inc: Deep Track Capital, LP (8.46%, Schedule 13G/A, filed 2026-05-15), RTW Investments, LP (8.1%, Schedule 13G/A, filed 2025-08-14), JANUS HENDERSON GROUP Ltd. (6.5%, Schedule 13G/A, filed 2026-08-13) and Fmr LLC (6.4%, Schedule 13G, filed 2026-11-05).
Who are the largest shareholders of Tarsus Pharmaceuticals Inc?
By the share each holder's latest filing reports, the largest holders of Tarsus Pharmaceuticals Inc on this page are Deep Track Capital, LP (8.46%), RTW Investments, LP (8.1%) and JANUS HENDERSON GROUP Ltd. (6.5%).
When did Deep Track Capital, LP buy into Tarsus Pharmaceuticals Inc?
The filings give report dates, not purchase dates. The earliest filing from Deep Track Capital, LP on this page is the Schedule 13G, filed 2025-07-28, reporting 5.6%; its latest, Schedule 13G/A filed 2026-05-15, reports 8.46%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Tarsus Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 4, 2026 | Acquired Alkeus Pharmaceuticals, Inc. | $270M | Acquisition | Source |
| July 13, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Tarsus Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.